Lupin Signs Canada Licensing Pact with Spektus for Novel Antidepressant DeslaFlex
Mumbai: Global pharma major Lupin Limited has signed a licence and supply agreement with Spektus Pharma, a specialty pharmaceutical company, to commercialize the novel antidepressant DeslaFlex in Canada.
DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using its proprietary Flexitab™ oral drug-delivery platform.
The strategic partnership combines Lupin’s established commercial footprint in Canada with Spektus’s expertise in developing differentiated and novel formulations. The collaboration aims to successfully introduce DeslaFlex™ in the Canadian market while building a platform for future launches. The agreement further strengthens Lupin’s central nervous system (CNS) portfolio with physician-endorsed, value-added therapies aligned with a supportive regulatory environment.
“This milestone reinforces our long-term commitment to advancing Lupin’s CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling more personalized, patient-focused care,” said Claus Jepsen, President, Global Specialty, Lupin.
Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said the partnership marks a key transition for the company from development to commercial execution. He added that Lupin’s global brand and strong commercial presence in Canada make it an ideal partner to unlock the full value of DeslaFlex™ in the market.
Lupin Limited, headquartered in Mumbai, operates in over 100 markets with a strong presence in branded and generic formulations, complex generics, biotechnology products, and APIs. The company has a significant footprint across CNS and other major therapeutic areas globally.
